Abstract
Background People with HIV (PWH) are at elevated risk for atherosclerotic cardiovascular disease (ASCVD). Underrepresented racial and ethnic groups (UREGs) with HIV in the southern U.S. are disproportionately affected, yet whether cardiology specialist care for this at-risk group improves blood pressure and lipid control or prevents cardiovascular events is unknown.
Methods We evaluated a cohort of PWH from UREGs at elevated ASCVD risk without known cardiovascular disease who received HIV-related care from 2015–2018 at four academic medical centers in the Southern United States with follow up through 2020. Primary outcomes were blood pressure control (<140/90 mmHg) and lipid control (LDL-C ≤ 100 mg/dl) over 2 years and time to first major adverse cardiovascular (MACE) event. Statistical analyses were adjusted for cohort/site and patient factors including HIV measures and comorbidities.
Results Among 3972 included PWH (median age 47 years old, 32.6% female) without diagnosed cardiovascular disease, 276 (6.9%) had a cardiology clinic visit. Cardiology clinic visits were not significantly associated with subsequent blood pressure control (adjusted OR 0.78, 95% CI 0.49-1.24, p=0.29) or lipid control (adjusted OR 2.25, 95% CI 0.72-7.01, p=0.16). Over a median follow up of 5 years, patients who had a cardiology clinic visit had higher risk of MACE, overall mortality, and falsification endpoints (hospitalization or death from accident/trauma and pneumonia/sepsis) indicating a higher risk group overall, even after adjusting for measured risk factors.
Conclusions Among UREG PWH at elevated cardiovascular risk, a cardiology clinic visit was not associated with improved cardiovascular risk factors or reduced risk of cardiovascular events. Our study suggests that seeing a cardiologist is not alone sufficient to promote cardiovascular health or prevent cardiovascular events among PWH, but with low confidence given the higher risk among those who had a cardiology visit.
What is known?
People with HIV are at increased cardiovascular risk, and the burden of both cardiovascular disease and HIV are high among people from underrepresented racial and ethnic groups who live in the Southern United States.
Treating people with HIV at elevated cardiovascular risk with statins reduces risk of cardiovascular events.
What the study adds?
Among people with HIV at elevated cardiovascular risk from underrepresented racial and ethnic groups who received care at four academic medical centers in the southern United States, cardiology clinic visits were not associated with better lipid control, blood pressure control, or prevention of cardiovascular events.
People with HIV who attended a cardiology clinic visit had higher risk of cardiovascular events and mortality.
Competing Interest Statement
CTL is on the advisory board for Theratechnologies outside the scope of this work.
Clinical Trial
This is not a clinical trial, but it was registered on clinicaltrials.gov, NCT04025125.
Funding Statement
Research reported in this publication was supported by the National Institute of Minority Health and Health Disparities (R01MD013493, PI: Bloomfield); the National Institutes of Health (Okeke, PI: K23HL137611-04; R01MH113438, PI: Pettit); the National Institute of General Medical Sciences (P20GM130457, PI: Meissner); the Tennessee Center for AIDS Research (P30AI110527, PI: Pettit); and powered by PCORnet®. PCORnet has been developed with funding from the Patient-Centered Outcomes Research Institute® (PCORI®). Dr. Durstenfeld is funded by NIH/NHLBI grant K23HL172699. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH or views of organizations participating in, collaborating with, or funding PCORnet or of PCORI.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Duke University Health System IRB approved this study with a waiver of informed consent as the single IRB with the other sites relying on this IRB.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
A de-identified dataset is currently being generated to be posted to the NIH's BioData Catalyst.
